

## Collaborating for Cures

### Leveraging Global Public-Private Partnerships to Accelerate Biopharmaceuticals Development

First Joint IMI & C-Path Forum on the Value of PPPs

Thursday 7 March 2013 – Brussels, Belgium

The Sheraton Hotel, Brussels Airport

9:00-10:00      *Registration and refreshments*

#### **10:00-10:30      Welcome and introduction**

Michel Goldman, Executive Director, IMI

Martha Brumfield, President and CEO, C-Path

#### **10:30-12:30      Innovative solutions to shared challenges**

Roundtable discussion – what challenges do PPPs face in areas such as knowledge management, sustainability, data sharing protection, intellectual property, ensuring industry involvement, addressing patients' concerns, and evaluating the added value of PPPs? What solutions are in place and what challenges remain?

Chair: Orla Smith, Managing Editor, Science Translational Medicine

Panellists:

- Maria Freire, President, Foundation for the National Institutes of Health (FNIH)
- Tania Bubela, University of Alberta
- Alastair Benbow, Chief Executive, The Age of the Brain
- Hans-Georg Eichler, Senior Medical Officer, EMA
- ShaAvhree Buckman-Garner, Director, Drug Evaluation & Translational Science, FDA
- Richard Bergström, Director General, EFPIA

12:30-13:30      *Lunch*

#### **13:30-15:30      IMI and C-Path collaboration on Alzheimer's disease**

Session Chair: Dr Elisabetta Vaudano, IMI Principal Scientific Manager

Speakers: IMI's PharmaCog project – Jill Richardson, GlaxoSmithKline

IMI's EMIF project - Simon Lovestone, King's College London

C-Path's Coalition Against Major Diseases (CAMD) - Diane Stephenson, Executive Director

Panel discussion on the outcomes of the projects and their relevance in particular to regulators and patients

- Jill Richardson, GSK
- Simon Lovestone, King's College London
- Diane Stephenson, CAMD

- Maria Isaac, EMA
- Russel G. Katz, FDA
- Maria Carrillo, Alzheimer's Association
- Jean Georges, Alzheimer Europe

*15:30-16:00            Tea / coffee break*

**16:00-17:30            IMI and C-Path collaboration on tuberculosis**

Session Chair: Dr Elisabetta Vaudano, IMI Principal Scientific Manager

Speakers: IMI's Predict-TB project – Justin Green, GSK & Gerry Davis, University of Liverpool  
C-Path's Critical Path to TB Drug Regimens (CPTR) project - Debra Hanna, Executive Director

Panel discussion on the outcomes of the projects and their relevance in particular to regulators and patients

- Justin Green, GlaxoSmithKline
- Gerry Davies, University of Liverpool
- Debra Hanna, CPTR
- Bron Kisler, Clinical Data Interchange Standards Consortium (CDISC)
- Ed Cox, FDA
- Joe Toerner, FDA
- Marco Cavaleri, EMA

**17:30-17:50            Conclusions**

Michel Goldman, Executive Director, IMI

Martha Brumfield, President and CEO, C-Path

*17:50                    End of the meeting*